Literature DB >> 17482934

Study of prostate cancer pathologic features in Chinese populations.

Ai-Ying Chuang1, Shu-Jen Chang, Cheng-Fang Horng, Mei-Hua Tsou.   

Abstract

OBJECTIVES: To report the pathologic features of prostate cancer and its clinical outcome in the Chinese population in Taiwan.
METHODS: A total of 139 radical prostatectomy specimens removed at Koo Foundation Sun Yat-Sen Cancer Center from 1993 to 2001 were reviewed.
RESULTS: The median patient age was 69 years. The histologic type was acinar adenocarcinoma in 137, mucinous adenocarcinoma in 1, and ductal adenocarcinoma in 1. The median tumor number in each prostate gland was 2. The main tumor location was distributed in peripheral zone (76.3%), followed by the transitional zone (15.1%). The Gleason score of the largest tumor was 2 to 4 in 1.5%, 5 to 6 in 7.9%, 7 in 48.9%, and 8 to 10 in 41.7%. Extraprostatic tumor extension, seminal vesicle invasion, and lymph node metastasis were found in 59.0%, 28.8%, and 13.7% of the patients, respectively. Of the 139 specimens, 56 (40.3%), 64 (46.1%), and 19 (13.7%) were pathologic Stage T2, T3, and T4, respectively. The clinical stage (P = 0.0059), serum prostate-specific antigen (PSA) level (greater than 20 ng/mL versus 10 ng/mL or less, P = 0.002), extraprostatic extension (P = 0.0012), seminal vesicle invasion (P <0.0001), and surgical margin status (P <0.0001) were all significant factors for disease progression on univariate analysis. On multivariate analysis, the serum PSA level (greater than 20 ng/mL versus 10 ng/mL or less, P = 0.03), seminal vesicle invasion (P = 0.02), and surgical margin status (P = 0.02) remained significant.
CONCLUSIONS: The patients with prostate cancer cared for at the Koo Foundation Sun Yat-Sen Cancer Center were older and had greater PSA levels, a more advanced stage, higher grade tumors, and high positive surgical margin rates. Increased public awareness and implementing a PSA screening program in Taiwan are of crucial importance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17482934     DOI: 10.1016/j.urology.2007.01.051

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  A population-based nested case-control study in taiwan: use of 5α-reductase inhibitors did not decrease prostate cancer risk in patients with benign prostate hyperplasia.

Authors:  Ji-An Liang; Li-Min Sun; Ming-Chia Lin; Shih-Ni Chang; Fung-Chang Sung; Chih-Hsin Muo; Chia-Hung Kao
Journal:  Oncologist       Date:  2012-06-20

2.  Ductal adenocarcinoma of the prostate: a Hong Kong case series.

Authors:  Raymond Wai Man Kan; Chi Fai Kan; Joseph Hon Ming Wong; Kenneth Kam Fung Fu; Chi Fai Ng; Steve Wai Hee Chan
Journal:  Int Urol Nephrol       Date:  2014-07-31       Impact factor: 2.370

3.  Evaluation of prostate cancer characteristics in four populations worldwide.

Authors:  Charnita M Zeigler-Johnson; Hanna Rennert; R Devi Mittal; Mohamed Jalloh; Rajeev Sachdeva; S Bruce Malkowicz; Anil Mandhani; B Mittal; Serigne M Gueye; Timothy R Rebbeck
Journal:  Can J Urol       Date:  2008-06       Impact factor: 1.344

4.  Clinical and pathological characteristics of screen-detected versus clinically diagnosed prostate cancer in Nanjing, China.

Authors:  LiXin Hua; Di Qiao; Bin Xu; NingHan Feng; Gong Cheng; JieXiu Zhang; NingHong Song; Wei Zhang; Jie Yang; JianGang Chen; YuanGeng Sui; HongFei Wu
Journal:  Med Oncol       Date:  2010-01-14       Impact factor: 3.064

5.  Scientific publications in nephrology and urology journals from Chinese authors in East Asia: a 10-year survey of the literature.

Authors:  Jing Xu; Zhi-Guo Mao; Mei Kong; Liang-Hao Hu; Chao-Yang Ye; Cheng-Gang Xu; Shu Rong; Li-Jun Sun; Jun Wu; Bing Dai; Dong-Ping Chen; Yu-Xian Zhu; Yi-Xiang Zhang; Yu-Qiang Zhang; Xue-Zhi Zhao; Chang-Lin Mei
Journal:  PLoS One       Date:  2011-04-08       Impact factor: 3.240

6.  Outcomes of patients with lymph node metastasis treated with radical prostatectomy and adjuvant androgen deprivation therapy in a Chinese population: results from a cohort study.

Authors:  Xiaojian Qin; Chengtao Han; Hailiang Zhang; Bo Dai; Yao Zhu; Yijun Shen; Yiping Zhu; Guohai Shi; Dingwei Ye
Journal:  World J Surg Oncol       Date:  2015-05-06       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.